NASDAQ:VANI - Nasdaq - US92854B1098 - Common Stock - Currency: USD
VANI is set to spin off Cortigent, aiming to sharpen its focus on drug implants and unlock long-term value for both entities.
All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study...
ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vivani Medical (NASDAQ:VANI) just reported results for the second quarter of 20...
VANI stock results show that Vivani Medical beat analyst estimates for earnings per share the second quarter of 2024.
Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes Vivani CEO Adam...
Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabolic decline and...
Heartland Advisors, an investment management company, released its “Heartland Value Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund was down 5.63% in the first quarter compared to a 7.74% fall for the Russell 2000 Value Index. The fund outperformed the benchmark over the past 1, 3, […]
Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in obese and overweight subjects...
Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company’s once...
The company said on Wednesday that a single administration of the implant in healthy rats resulted in 20% lower body weight through a 91-day treatment period as compared to a control group that received a sham implant.
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide...